Because the drug doesn’t target the brain, it has less potential for addiction. Learn why this could help the opioid crisis.

White House Press Secretary Karoline Leavitt told reporters that President Trump would be implementing tariffs on Canada, ...

This new nonaddictive alternative is the first of its kind that interrupts the pain signal before it reaches the brain.

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

A new non-opioid painkiller, JournaVX, has received approval from the FDA, marking the first new type of pain medication in ...

Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.

The FDA has approved suzetrigine, a new, non-opioid medication for adults with moderate to severe acute pain.

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...

Journavx (suzetrigine) is said to reduce pin by "targeting a pain-signaling pathway involving sodium channels in the ...

Suzetrigine, to be sold under the brand name Journavx, is the first new type of pain medicine approved by the FDA in more ...

The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid medication for treating moderate to severe acute pain in adults. Journavx, approved ...

Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...